C07K 14/485
Epidermal growth factor [egf], i.e. urogastrone
Official title: Epidermal growth factor [EGF], i.e. urogastrone
C07K14/485 (Epidermal growth factor [egf], i.e. urogastrone) appears on 353 US grants and 476 published applications in this corpus.
Search patents in C07K- Granted patents
- 353
- Published applications
- 476
- Assignees
- 290
- Inventors
- 1,061
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 2 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 5 | 0 |
| 1989 | 5 | 0 |
| 1990 | 3 | 0 |
| 1991 | 3 | 0 |
| 1992 | 5 | 0 |
| 1993 | 9 | 0 |
| 1994 | 3 | 0 |
| 1995 | 3 | 0 |
| 1996 | 3 | 0 |
| 1997 | 11 | 0 |
| 1998 | 11 | 0 |
| 1999 | 12 | 0 |
| 2000 | 6 | 0 |
| 2001 | 6 | 1 |
| 2002 | 5 | 5 |
| 2003 | 3 | 24 |
| 2004 | 2 | 15 |
| 2005 | 5 | 14 |
| 2006 | 8 | 13 |
| 2007 | 5 | 8 |
| 2008 | 5 | 10 |
| 2009 | 11 | 16 |
| 2010 | 6 | 18 |
| 2011 | 5 | 18 |
| 2012 | 10 | 15 |
| 2013 | 9 | 18 |
| 2014 | 9 | 51 |
| 2015 | 32 | 23 |
| 2016 | 17 | 24 |
| 2017 | 19 | 22 |
| 2018 | 14 | 17 |
| 2019 | 17 | 27 |
| 2020 | 12 | 22 |
| 2021 | 15 | 26 |
| 2022 | 12 | 17 |
| 2023 | 9 | 24 |
| 2024 | 6 | 22 |
| 2025 | 12 | 18 |
| 2026 | 11 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Engineered NRG-1 variants with improved selectivity toward ErbB4 but not against ErbB38 Sep 2026US 12,729,229 B2Amgen Inc.
- Bi-specific fusion proteins25 Aug 2026US 12,715,937 B2Silver Creek Pharmaceuticals, Inc.
- Bi-specific fusion proteins4 Aug 2026US 12,698,347 B2Silver Creek Pharmaceuticals, Inc.
- Engineered NRG-1 variants with improved selectivity toward ErbB4 but not against ErbB328 Jul 2026US 12,692,294 B2Amgen Inc.
- Gla domains as therapeutic agents14 Jul 2026US 12,678,481 B2Gladiator Biosciences, Inc.
- Modular re-targeting of rhabdoviral (g) glycoproteins from their natural receptors24 Sep 2026US 2026/0285912 A1Vyriad, Inc.
- Antibody binding to fibrin, fibrinolytic protein containing antibody, and pharmaceutical formulation containing protein27 Aug 2026US 2026/0250366 A1Rin Institute Inc.
- In vivo production of proteins25 Jun 2026US 2026/0174909 A1ModernaTX, Inc.
- Neuregulin and use thereof16 Apr 2026US 2026/0103496 A1Zensun (Shanghai) Science & Technology, Co., Ltd.
- Chimeric antigen receptor-expressing cell that targets egfr12 Mar 2026US 2026/0070956 A1Kyoto Prefectural Public University Corporation
Most cited
By later US patents
- Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and compositions thereof519US 5,723,323 A1998
- Process for the production of stochastically-generated transcription or translation products347US 5,814,476 A1998
- Process for the production of expression vectors comprising at least one stochastic sequence of polynucleotides330US 5,824,514 A1998
- Process for the production of stochastically-generated peptides,polypeptides or proteins having a predetermined property317US 5,817,483 A1998
- Process for obtaining DNA, RNA, peptides, polypeptides, or proteins, by recombinant DNA technique289US 5,976,862 AIxsys, Inc. · 1999